Rozanolixizumab - UCB Pharma

Drug Profile

Rozanolixizumab - UCB Pharma

Alternative Names: UCB7665

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Class Monoclonal antibodies
  • Mechanism of Action Fc receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura; Myasthenia gravis
  • No development reported Immunological disorders

Most Recent Events

  • 14 Jun 2018 Updated interim efficacy and adverse events data from a phase II trial in Idiopathic thrombocytopenic purpura (Immune thrombocytopenic purpura) presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 09 Dec 2017 Interim adverse events data from a phase II and phase I trial in Immune thrombocytopenic purpura presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-HEM-2017)
  • 09 Dec 2017 Interim efficacy data from a phase II trial in Immune thrombocytopenic purpura presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top